9 Other revenues

9 Other revenues

 

 

 

€ million

2019

2018

Revenue generated by means of profit-sharing agreements

0

11

Upfront payments, milestone payments and reimbursements

46

34

Contract manufacturing revenues

109

83

Total other revenue

155

128

 

 

 

During 2019, UCB received milestone payments and reimbursements from different parties, mainly:

  • Otsuka for co-development of E Keppra® and Neupro® in Japan;
  • Daiichi Sankyo for Vimpat® in Japan;
  • Astellas for Cimzia® in Japan;
  • Biogen for co-development of antibody dapirolizumab pegol.

The revenue from contract manufacturing activities is mainly linked to the entering into toll manufacturing agreements after divestiture of established brands.

In 2018, the revenue generated through profit-sharing agreements relates mainly to revenue from the co-promotion of Dafiro®. This was related to the business of “Innere Medizin” which was divested in 2018.